rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Arcturus Therapeutics Holdings Inc.

ARCT · Nasdaq

Health CareBiotechnologyLeading

ARCT stood above a rising 150-day average in 9 of the last 52 weekly readings, including each of the last 9 weeks. It is 12.1% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
9 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
129 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$40KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders129+12 on the quarter
New · exited21 · 8
Reported value$167.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FEDERATED HERMES, INC.unchanged · filed 12 Aug 20263,303,640$22.2M00.0%
ARK Investment Management LLCadded · filed 14 Aug 20262,901,635$19.5M+132,117+4.8%
BlackRock, Inc.added · filed 7 Aug 20262,614,012$17.6M+7310.0%
Sumitomo Mitsui Trust Group, Inc.reduced · filed 30 Jul 20261,963,123$13.2M-325,812−14.2%
Amova Asset Management Americas, Inc.reduced · filed 13 Aug 20261,960,458$13.1M-328,477−14.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,114,956$7.5M+7,936+0.7%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20261,091,137$7.3M+9,353+0.9%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026951,575$6.4M-26,347−2.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026693,660$4.7M+32,732+5.0%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026675,014$4.5M+513,736+318.5%
31 Mar 2023 – 30 Jun 2026
97127156Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Edward W. Holmes Company insiderDirector · last 5 Jun 20260 · 0
James F. Barlow Company insiderDirector · last 5 Jun 20260 · 0
Jing L. Marantz Company insiderDirector · last 5 Jun 20260 · 0
John Markels Company insiderDirector · last 5 Jun 20260 · 0
Magda Marquet Company insiderDirector · last 5 Jun 20262 · 0
Moncef Slaoui Company insiderDirector · last 5 Jun 20260 · 0
Peter C. Farrell Company insiderDirector · last 5 Jun 20262 · 0
Dennis Mulroy Company insiderChief Financial Officer · last 1 May 20260 · 0
Joseph E. Payne Company insiderPresident and CEO · last 17 Dec 20253 · 0
Joseph Roberts Company insiderController · last 17 Dec 20250 · 0
Lance Kurata Company insiderChief Legal Officer · last 17 Dec 20250 · 0
Pad Chivukula Company insiderChief Scientific Officer & COO · last 17 Dec 20250 · 32

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-93.0%
Free cash flow marginFY 2025 · to 31 Dec 2025-90.8%
Return on capital employedFY 2025 · to 31 Dec 2025-32.5%
Research spendFY 2025 · to 31 Dec 2025137%
Share count trendFY 2025 · to 27 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$230.9M
Free cash flowFY 2025 · to 31 Dec 2025−$74.5M

Analyst forecasts

No analyst forecasts yet.